Gyre Therapeutics (GYRE) Enterprise Value: 2009-2025
Historic Enterprise Value for Gyre Therapeutics (GYRE) over the last 17 years, with Sep 2025 value amounting to $693.9 million.
- Gyre Therapeutics' Enterprise Value fell 41.28% to $693.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $582.9 million, marking a year-over-year decrease of 46.31%. This contributed to the annual value of $1.1 billion for FY2024, which is 1759.31% up from last year.
- Gyre Therapeutics' Enterprise Value amounted to $693.9 million in Q3 2025, which was up 3.24% from $672.1 million recorded in Q2 2025.
- Gyre Therapeutics' Enterprise Value's 5-year high stood at $1.5 billion during Q1 2024, with a 5-year trough of -$20.6 million in Q4 2021.
- In the last 3 years, Gyre Therapeutics' Enterprise Value had a median value of $693.9 million in 2025 and averaged $636.6 million.
- Its Enterprise Value has fluctuated over the past 5 years, first slumped by 341.59% in 2021, then surged by 58,733.33% in 2024.
- Over the past 5 years, Gyre Therapeutics' Enterprise Value (Quarterly) stood at -$20.6 million in 2021, then spiked by 202.35% to $21.1 million in 2022, then skyrocketed by 190.15% to $61.3 million in 2023, then spiked by 1,759.31% to $1.1 billion in 2024, then slumped by 41.28% to $693.9 million in 2025.
- Its Enterprise Value was $693.9 million in Q3 2025, compared to $672.1 million in Q2 2025 and $729.0 million in Q1 2025.